EpiCept to Report Second Quarter 2012 Operating and Financial Results on August 8, 2012
TARRYTOWN, N.Y.--(BUSINESS WIRE)--
Regulatory News:
EpiCept Corporation (Nasdaq OMX Stockholm Exchange and OTCQX: EPCT)
announced today that it will host a conference call to discuss second
quarter 2012 operating and financial results on Wednesday, August 8,
2012 at 9:00 a.m. Eastern time. The call will follow the release of
these financial results earlier in the day at 12:01 a.m. Eastern time.
To participate in the live call and be able to participate in the
question and answer session, please dial from the U.S. and Canada (877)
809-8594 or from international locations (706) 758-9407 (please
reference access code 17527052) prior to the start of the conference.
The conference call will also be broadcast live in listen-only mode on
the Internet and may be accessed at www.epicept.com.
The webcast will be archived for 90 days.
A telephone replay of the call will be available for seven days by
dialing from the U.S. and Canada (855) 859-2056 or from international
locations (404) 537-3406 (please reference reservation number 17527052).
About EpiCept Corporation
EpiCept is focused on the development and commercialization of
pharmaceutical products for the treatment of pain and cancer. The
Company's pain portfolio includes AmiKet™, a prescription topical
analgesic cream in late-stage clinical development designed to provide
effective long-term relief of pain associated with peripheral
neuropathies. The Company's product Ceplene®, when used
concomitantly with low-dose interleukin-2 (IL-2) is intended as
remission maintenance therapy in the treatment of acute myeloid leukemia
(AML) for adult patients who are in their first complete remission. The
Company sold all of its rights to Ceplene® in Europe and
certain Pacific Rim countries and a portion of its remaining Ceplene®
inventory to Meda AB. Ceplene® is licensed to MegaPharm Ltd.
to market and sell in Israel and EpiCept has retained its rights to
Ceplene® in all other countries, including countries in North
and South America. The Company has other oncology drug candidates in
clinical development that were discovered using in-house technology and
have been shown to act as vascular disruption agents in a variety of
solid tumors.
Forward-Looking Statements
This news release and any oral statements made with respect to the
information contained in this news release contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include statements
which express plans, anticipation, intent, contingency, goals, targets,
future development and are otherwise not statements of historical fact.
These statements are based on our current expectations and are subject
to risks and uncertainties that could cause actual results or
developments to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. Factors that may cause actual results or developments to
differ materially include: the risk that Ceplene® will not
receive regulatory approval or marketing authorization in the United
States or Canada, the risk that Ceplene® will not achieve
significant commercial success, the risks associated with the adequacy
of our existing cash resources and our ability to continue as a going
concern, the risks associated with our ability to continue to meet our
obligations under our existing debt agreements, the risk that Azixa™
will not receive regulatory approval or achieve significant commercial
success, the risk that we will not receive any significant payments
under our agreement with Myrexis, the risk that clinical trials for
AmiKet™ or crolibulinTM will not be successful, the risk that
AmiKet™ or crolibulinTM will not receive regulatory approval
or achieve significant commercial success, the risk that we will not be
able to find a partner to help conduct the Phase III trials for AmiKet™
on attractive terms, a timely basis or at all, the risk that our other
product candidates that appeared promising in early research and
clinical trials do not demonstrate safety and/or efficacy in
larger-scale or later-stage clinical trials, the risk that we will not
obtain approval to market any of our product candidates, the risks
associated with dependence upon key personnel, the risks associated with
reliance on collaborative partners and others for further clinical
trials, development, manufacturing and commercialization of our product
candidates; the cost, delays and uncertainties associated with our
scientific research, product development, clinical trials and regulatory
approval process; our history of operating losses since our inception;
the highly competitive nature of our business; risks associated with
litigation; and risks associated with our ability to protect our
intellectual property. These factors and other material risks are more
fully discussed in our periodic reports, including our reports on Forms
8-K, 10-Q and 10-K and other filings with the U.S. Securities and
Exchange Commission. You are urged to carefully review and consider the
disclosures found in our filings which are available at www.sec.gov
or at www.epicept.com.
You are cautioned not to place undue reliance on any forward-looking
statements, any of which could turn out to be wrong due to inaccurate
assumptions, unknown risks or uncertainties or other risk factors.
*Azixa is a registered trademark of Myrexis, Inc.
EPCT-GEN
EpiCept Corporation:
Robert W. Cook, 914-606-3500
rcook@epicept.com
or
Media:
Feinstein
Kean Healthcare
Greg Kelley, 617-577-8110
gregory.kelley@fkhealth.com
or
Investors:
LHA
Kim
Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
or
Bruce
Voss, 310-691-7100
bvoss@lhai.com
Source: EpiCept Corporation
News Provided by Acquire Media
Close window | Back to top
